78907-89-8

Upstream product

• 78907-88-7 (2R)-2-benzyloxy-4-oxo-1,6-hexanedial 4-ethylene dithioacetal 
• 77003-65-7 (3R,4S,5R)-3,4,5-trihydroxycyclohexanone ethylene dithioacetal 
• 78907-87-6 (3R,4S,5R)-5-O-benzyl-3,4,5-trihydroxycyclohexanone ethylene dithioacetal 

Downstream Products

• 78907-90-1 (3R)-3-benzyloxy-5-oxo-1-cyclopentene-1-carbaldehyde 1-propylene-acetal 5-ethylene-dithioacetal 
• 82302-57-6 11α-hydroxy-13-oxaprostanoic acid 
• 78907-91-2 (3R)-benzyloxy-5-oxo-1-cyclopentene-1-carbaldehyde 1-propylene acetal 
• 78907-94-5 (1R,2R,3S)-benzyloxy-3-hydroxy-2-cyclopentanecarbaldehyde trimethylene-acetal 
• 78963-78-7 (1R,2S,3S)-benzyloxy-3-hydroxy-2-cyclopentanecarbaldehyde trimethylene-acetal 
• 78907-93-4 (1S,2R,3R)-benzyloxy-3-heptyloxy-2-(oxo-5-ethylene-dithioacetal)cyclopentanecarbaldehyde trimethylene-acetal 
• 78907-95-6 1α-benzyloxy-3α-(1,3-dioxa-2-cyclohexyl)-2β-heptyloxycyclopentane 
• 78907-92-3 (1S,2R,3R)-benzyloxy-3-hydroxy-2-(oxo-5-ethylene-dithioacetal)cyclopentanecarbaldehyde trimethylene-acetal 
• 78907-98-9 (1S,2R,3R)-benzyloxy-3-heptyloxy-2-cyclopentanecarbaldehyde 
• 78907-97-8 (1R,2R,3S)-benzyloxy-3-oxo-2-cyclopentanecarbaldehyde trimethylene-acetal 

Relevant academic research and scientific papers

Synthesis of Enantiomerically Pure Substituted Cyclopentenes from (-)-Quinic Acid

The synthesis of a large variety of enantiomerically pure substituted reactive cyclopentenes 16, 23, 24 and 28 have been synthesized from the readily available (-)-quinic acid 1.The straightforward strategy involves a high-yielding intramolecular aldoliza

Hetero-prostaglandin derivatives and processes for preparing them

Prostanoic acid derivatives represented by the general formula: STR1 in which X represents hydrogen or hydroxy, X1 represents hydrogen or X and X1, when they are taken together with the carbon atom to which they are attached, represent a carbonyl group and Z represents hydrogen or hydroxy and pharmaceutically acceptable alkali metal salts thereof. They can be used as bronchodilators and/or inhibitors of blood-platelet aggregation.